Alemtuzumab Induction Is Associated With an Equalization of Outcomes Between White and African American Kidney Transplant Recipients

Exp Clin Transplant. 2019 Apr;17(2):196-201. doi: 10.6002/ect.2017.0065. Epub 2017 Dec 5.

Abstract

Objectives: Our aim was to assess outcomes in White and African American kidney transplant recipients after induction with alemtuzumab.

Materials and methods: We performed a retrospective study of 464 patients who received deceased-donor kidney transplants and were induced with alem-tuzumab between March 2006 and May 2015. We evaluated ethnic influences on patient and graft survival, delayed graft function, allograft failure, and rejection.

Results: There were 337 White (67.3%) and 127 African American (25.3%) patients. We observed no significant differences in 1-, 3-, 5-, and 7- year death-censored graft survival. We also observed no significant differences in 1-, 3-, and 5-year patient survival rates. Having African American ethnicity was not a significant predictor of rejection, graft survival, or patient survival.

Conclusions: Our results indicate that recipient ethnicity is not a predictor of rejection, graft survival, or patient survival. White and African American kidney transplant recipients induced with alemtuzumab experienced an equalization of outcomes.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Alemtuzumab / administration & dosage*
  • Alemtuzumab / adverse effects
  • Black or African American*
  • Delayed Graft Function / ethnology
  • Delayed Graft Function / immunology
  • Delayed Graft Function / prevention & control
  • Female
  • Graft Rejection / ethnology
  • Graft Rejection / immunology
  • Graft Rejection / prevention & control
  • Graft Survival / drug effects
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Immunosuppressive Agents / adverse effects
  • Kidney Transplantation* / adverse effects
  • Kidney Transplantation* / mortality
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Transplant Recipients*
  • Treatment Outcome
  • White People*

Substances

  • Immunosuppressive Agents
  • Alemtuzumab